Advanced search    

Search: authors:"C. Roux"

17 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Évaluation et réhabilitation précoce du patient ventilé — Comment prédire l’encombrement bronchique postextubation ?

C. Roux 0 ) Service de ranimation polyvalente, centre hospitalier de Roanne , 28, rue de Charlieu, BP 511, F-42328 Roanne cedex, France e-mail : Evaluation and early rehabilitation of ventilated

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

. K. Lippuner has served as a board member for Amgen Inc., Lilly, MSD, and UCB. C. Roux has served as a board member for Amgen Inc. and MSD; as a consultant and speaker for Amgen Inc., Eli Lilly, and

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

, France 3 C. Roux Rheumatology Department, Cochin Hospital , Assistance Publique-Hpitaux de Paris, Paris Descartes University , Paris, France 4 F. Mercier Stat-Process, Port-Mort, France Summary This ... (s) and source are credited. Conflicts of interest C. Roux has received research grants and/or speakers fees from Alliance, Amgen, Lilly, MSD, Novartis, GSK-Roche, Servier and Wyeth.

Disruption of the interaction between PMCA2 and calcineurin triggers apoptosis and enhances paclitaxel-induced cytotoxicity in breast cancer cells

Cancer is caused by defects in the signalling mechanisms that govern cell proliferation and apoptosis. It is well known that calcium-dependent signalling pathways play a critical role in cell regulation. A tight control of calcium homeostasis by transporters and channel proteins is required to assure a proper functioning of the calcium-sensitive signal transduction pathways that ...

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

, Novartis, and Warner Chilcott and payment for development of educational programs from Amgen. C. Roux is a member of advisory boards and a consultant for Amgen, MSD, and Novartis. He also received grants

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

, Bridgewater, NJ, USA 6 Z. Man Centro TIEMPO , Buenos Aires, Argentina 7 C.-L. Benhamou INSERM Research Unit U658 , Orlans, France 8 C. Roux Paris Descartes University, Cochin Hospital , Paris, France Summary ... Gamble. A. Racewicz has no disclosures. C. Roux has received honoraria and research grants from the Alliance for Better Bone Health. C.L. Benhamou is a consultant and/or speaker for Amgen, Merck, Novartis

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis

. P. Devogelaer St-Luc University Hospital, Universit catholique de Louvain , UCL 5390, 1200 Brussels, Belgium 1 C. Roux Hpital Cochin, Universit Paris Descartes , Paris, France 2 A. Balogh Department

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

; Pr C. Roux). Peripheral osteoporotic fractures were determined by investigators from radiographs or hospital reports [20]. Standing body height was standardized and measured by Harpenden stadiometer

One year comparison between two add‐back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double‐blind trial

BACKGROUND: It has been proposed that hormonal supplementation during prolonged GnRH agonist therapy prevents hypoestrogenic side effects, including bone loss. The optimal combination for long‐term treatments with safe metabolic profile remains questionable. A norprogesterone derivative, promegestone, was assessed for the first time in a double‐blind trial. METHODS: Seventy‐eight ...

Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW)

, UK 11 K. G. Saag University of Alabama-Birmingham , Birmingham, AL, USA 12 C. Roux Paris Descartes University, Cochin Hospital , Paris, France 13 M. Rossini Department of Rheumatology, University of

Changes in body composition during post‐menopausal hormone therapy: a 2 year prospective study*

BACKGROUND: Post‐menopausal hormone therapy (pHT) induces changes in both body composition and bone mineral density (BMD). METHODS: In 109 post‐menopausal women beginning either tibolone 2.5 mg (n = 29), tibolone 1.25 mg (n = 42) or estradiol 2 mg plus norethisterone acetate 1 mg (E2 + NETA) (n = 38), we assessed body composition, total and regional BMD by dual energy X‐ray ...

Meiotic segregation analysis in spermatozoa of pericentric inversion carriers using fluorescence in-situ hybridization

BACKGROUND: Pericentric inversions are structural chromosomal abnormalities resulting from two breaks, one on either side of the centromere, within the same chromosome, followed by 180° rotation and reunion of the inverted segment. They can perturb spermatogenesis and lead to the production of unbalanced gametes through the formation of an inversion loop. METHODS: We report here ...

Absence of anti-Müllerian hormone (AMH) and M2A immunoreactivities in Sertoli cell-only syndrome and maturation arrest with and without AZF microdeletions

BACKGROUND: Some genes identified in the AZF locus are expressed only in germinal cells; others are ubiquitous. AZF microdeletions seem to occur at the earliest stages of ontogenetic development, and one might therefore assume that Sertoli cells preserve some immature characteristics and that their immunophenotype may be modified by the existence of a molecular defect. MATERIALS ...

The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design

Clinical Immunology and Rheumatology, University of Alabama-Birmingham , Birmingham, AL, USA 16 C. Roux Centre D'Evaluation Des Maladies Osseuses , Hpital Cochin, Paris, France 17 N. B. Watts Bone Health and

DNA and chromatin structure: Analysis of the sex chromosomal equipment in spermatozoa of a 47, XYY male using two-colour fluorescence in-situ hybridization

The sex chromosomes in spermatozoa of a 47, XYY fertile male were analysed simultaneously by dual fluorescence in-situ hybridization (FISH), with two probes (pHY2.1 and pXBR). Of the 100 000 cells analysed, 95 179 spermatozoa (95.18%) exhibited one or more hybridization signals. Of the hybridized nuclei, 85.37% showed a normal sex chromosome constitution (37.37% X-bearing cells and ...

AZFa deletions in Sertoli cell-only syndrome: a retrospective study

Lack of data on the genotype–phenotype relationship in cases of AZF microdeletions is due to the limited number of histological investigations in human male infertility cases. We investigated the possibility of retrospective detection of Yq11 microdeletions by using DNA extracted from diagnostic testicular biopsies. We used histological criteria to select two series of material: 22 ...

Bilan des examens chromosomiques de 277 couples candidats à l’injection intracytoplasmique de spermatozoïde

e D. HOCQUET C. ROUX M.-A. COLLONGE-RAME F. FELLMANN J.L. BRESSON Des 6tudes r6centes ont montr6 que la fr6quence des anomalies du caryotype est plus 61ev6e chez les patients i n d u s en ICSI que